PPARG and prostate carcinoma: In order to determine whether the dramatic effects on PC-3 by troglitazone were mediated through activation of PPARγ, the author also evaluated other PPARγ ligands such as BRL49653, 15dPGJ2, ciglitizone, and indomethacin on prostate cancer cell lines.